ERCC1

ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer

Z. C. Xu, Cai, H. Z., Li, X., Xu, W. Z., Xu, T., Yu, B., Zou, Q., Xu, L., Xu, Z. C., Cai, H. Z., Li, X., Xu, W. Z., Xu, T., Yu, B., Zou, Q., and Xu, L., “ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer”, vol. 15, p. -, 2016.

This study aims to investigate the association between ERCC1 codon C118T polymorphism and the response rate of platinum-based chemotherapy in patients with late-stage bladder cancer. A total of 41 eligible patients histologically confirmed as having stage IV muscle-invasive transitional cell carcinoma of the bladder were treated with platinum-based chemotherapy for 2-6 cycles. The genotypes of patients were determined by PCR amplification of genomic DNA followed by restriction enzyme digestion. Positive responses were categorized as complete and partial responses.

Effect of SNX-2112 on proliferation of esophageal cancer cells via regulation of excision repair cross-complementing 1, epidermal growth factor receptor, and p53 expression

C. Y. Li, Ren, Y. J., Li, Y. D., Li, C. Y., Ren, Y. J., and Li, Y. D., “Effect of SNX-2112 on proliferation of esophageal cancer cells via regulation of excision repair cross-complementing 1, epidermal growth factor receptor, and p53 expression”, vol. 15, p. -, 2016.

SNX-2112 is a potential molecular targeted therapeutic drug against esophageal cancer (EC). However, its exact mechanism of action remains to be explained. The aim of this study was to investigate the effect of SNX-2112 on excision repair cross- complementing 1 (ERCC1), epidermal growth factor receptor (EGFR), and p53, to elucidate the mechanism of action of SNX-2112 on EC. Fresh tumor sections were surgically obtained from 65 patients with EC, and the expression of ERCC1, EGFR, and p53 was determined by immunohistochemical staining.

Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer

D. L. Zheng, Tang, G. D., Chen, Y. N., Zhang, T., Qin, M. B., Zheng, D. L., Tang, G. D., Chen, Y. N., Zhang, T., Qin, M. B., Zheng, D. L., Tang, G. D., Chen, Y. N., Zhang, T., and Qin, M. B., “Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer”, vol. 15, p. -, 2016.

We conducted a prospective study to investigate whether ERCC1 rs11615 and rs3212986 and ERCC2 rs13181 and rs1799793 gene polymorphisms could serve as potential biomarkers for the prognosis of gastric cancer. Between January 2010 and December 2012, 246 patients with pathologically proven gastric cancer who were receiving platinum-based chemotherapy were recruited from the First Affiliated Hospital of Guangxi Medical University.

Association between ERCC1 and ERCC2 gene polymorphisms and susceptibility to pancreatic cancer

M. G. He, Zheng, K., Tan, D., Wang, Z. X., He, M. G., Zheng, K., Tan, D., Wang, Z. X., He, M. G., Zheng, K., Tan, D., and Wang, Z. X., “Association between ERCC1 and ERCC2 gene polymorphisms and susceptibility to pancreatic cancer”, vol. 15, p. -, 2016.

We conducted a study to investigate the association between ERCC1 (rs3212986) and ERCC2 (rs13181) gene polymorphisms and the risk of pancreatic cancer in a Chinese population. A total of 217 pancreatic cancer patients and 244 control subjects were recruited from the Nuclear Industry 215 Hospital of Shaanxi Province between February 2013 and December 2014. Genomic DNA was extracted from peripheral blood samples using a TIANamp Blood DNA Kit (Tiangen, Beijing, China) according to the manufacturer’s instructions.

Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients

G. Zhong, Li, H. K., Shan, T., and Zhang, N., “Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients”, vol. 14, pp. 17228-17234, 2015.

We investigate whether three common polymorphisms in ERCC1 and ERCC2 are predictor factors for the chemotherapy response, as well as the clinic outcome of patients with gastric cancer. Between May 2011 and May 2013, 263 patients with gastric cancer who were newly diagnosed by histopathology were enrolled in our study. Genotyping of the ERCC1 rs11615 and rs3212986, and ERCC2 rs1799793 polymorphisms were conducted by the polymerase chain reaction-restriction fragment length polymorphism assay.

Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer

W. H. Yu, Wang, Y. X., Guo, J. Q., Wang, Y. L., Zheng, J. S., and Zhu, K. X., “Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer”, vol. 14, pp. 17529-17535, 2015.

We performed a study to investigate the role of ERCC1 (rs11615, rs2298881, and rs3212986) and ERCC2 (rs13181, rs238406, and rs1799793) polymorphisms in the prognosis of gastric cancer. A total of 346 patients with gastric cancer were recruited between May 2009 and May 2012. Single nucleotide polymorphism genotyping was performed using the Sequenom MassARRAY platform. The GA+AA genotype of ERCC2 rs1799793 showed significant and favorable response to chemotherapy than the wide-type GG genotype in multivariate analysis (OR = 1.78, 95%CI = 1.13-2.81).

Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma

Z. H. Cao, Yin, H. P., Jiang, N., and Yu, B., “Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma”, vol. 14, pp. 10145-10151, 2015.

We aimed to evaluate the influence of four SNPs in ERCC1 and ERCC2 on the response to cisplatin-based treatment and on clinical outcome in patients with osteosarcoma. We identified 186 patients with osteosarcoma diagnosed between April 2009 and April 2011 who were eligible for inclusion in our study. Genotyping of ERCC1 rs11615, rs3212986, and rs2298881; and ERCC2 rs1799793 and rs13181 was conducted by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay.

Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma

Q. Zhang, Lv, L. Y., Li, B. J., Zhang, J., and Wei, F., “Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma”, vol. 14, pp. 11235-11241, 2015.

We assessed the role of single nucleotide polymorphisms (SNPs) in ERCC1 and ERCC2 genes in the clinical outcomes for osteosarcoma patients receiving cisplatin-based treatment. A perspective study was conducted on 260 patients with osteosarcoma during 2010 and 2011. A polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay was used to assess the ERCC1 rs11615 and rs3212986, and the ERCC2 rs1799793 and rs13181 gene polymorphisms.

Subscribe to ERCC1